MACTER currently exports to 15 countries, contributing 8% of total revenue, and plans to expand its reach to 30 countries by the end of FY27.
It is one of only two firms in Pakistan offering semaglutide in both prefilled syringe and multi-dose pen formats, while just four companies provide it in injectable form.
With rising global demand and more doctors prescribing semaglutide, management anticipates strong revenue growth led by Nova Nordisk and Ferozesons, followed by Macter and Getz.
Once the global patent expires, the company intends to export the product internationally. Management is also optimistic about the upcoming launch of tirzepatide, used for the same patient group, as its approval application has already been submitted to DRAP. Essential products make up 60–65% of the company’s portfolio with the remainder being non-essential items. Looking ahead, management expects first-quarter momentum to continue as new products gain traction.
https://dps.psx.com.pk/download/document/265317.pdf
